Zeteo Tech

Executive Summary

Zeteo Tech is developing a novel class of field-deployable biological mass spectrometers designed for real-time identification of airborne pathogens, toxins, and other bio-threats. The company’s patent-pending time-of-flight mass spectrometry platform enables rapid, sensitive detection of microbes, proteins, and lipids without the need for complex sample preparation or laboratory infrastructure. This capability positions Zeteo to address critical gaps in biodefense, infectious disease surveillance, and point-of-care diagnostics, where speed and portability are paramount. Founded in 2016 and based in San Diego, the company is venture-backed and targeting applications ranging from military base protection to hospital infection control. The system’s ability to simultaneously detect multiple threat classes differentiates it from conventional PCR or culture-based methods, which can take hours to days and require trained personnel. Zeteo’s technology has the potential to become a cornerstone of next-generation biodefense architectures, aligning with growing government investments in chemical, biological, radiological, and nuclear (CBRN) preparedness.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance for Respiratory Pathogen Panel55% success
• Q3 2026Strategic Partnership with U.S. Department of Defense70% success
• Q2 2026Series B Funding Raise80% success